Search research articles
Contact Us
Filters
Showing results (161-170 of 183) with videos related to
Page
of 19
Sort By:
European Urology Oncology
|
July 6, 2024
Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial
Tian Zhang, Lauren Howard, Bridget F Koontz, et al.
Cancer Medicine
|
September 15, 2023
Assessing the utility of molecular diagnostic classification for cancers of unknown primary
Elle C Moore, Gerard C Blobe, Nicholas C DeVito, et al.
Molecular Cancer Research : MCR
|
March 9, 2016
Development of a Novel c-MET-Based CTC Detection Platform
Tian Zhang, Rengasamy Boominathan, Brad Foulk, et al.
Cancer Medicine
|
March 2, 2021
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes
Andrew L Laccetti, Benjamin Garmezy, Lianchun Xiao, et al.
Cancers
|
August 12, 2022
The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma
Yu-Wei Chen, Matthew D Tucker, Landon C Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2021
Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer
Tracy L Rose, Michael R Harrison, Allison M Deal, et al.
JCO Precision Oncology
|
November 6, 2020
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer
Andrew J Armstrong, Jun Luo, David M Nanus, et al.
Nature Communications
|
May 24, 2024
Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer
Wolfgang Beckabir, Mi Zhou, Jin Seok Lee, et al.
The Lancet. Oncology
|
May 15, 2021
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
Evan Y Yu, Daniel P Petrylak, Peter H O'Donnell, et al.
Cancer
|
August 7, 2020
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer
Tian Zhang, Michael R Harrison, Peter H O'Donnell, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 183) with videos related to
Sort By:
Page
of 19
European Urology Oncology
|
July 6, 2024
Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial
Tian Zhang, Lauren Howard, Bridget F Koontz, et al.
Cancer Medicine
|
September 15, 2023
Assessing the utility of molecular diagnostic classification for cancers of unknown primary
Elle C Moore, Gerard C Blobe, Nicholas C DeVito, et al.
Molecular Cancer Research : MCR
|
March 9, 2016
Development of a Novel c-MET-Based CTC Detection Platform
Tian Zhang, Rengasamy Boominathan, Brad Foulk, et al.
Cancer Medicine
|
March 2, 2021
Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes
Andrew L Laccetti, Benjamin Garmezy, Lianchun Xiao, et al.
Cancers
|
August 12, 2022
The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma
Yu-Wei Chen, Matthew D Tucker, Landon C Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2021
Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer
Tracy L Rose, Michael R Harrison, Allison M Deal, et al.
JCO Precision Oncology
|
November 6, 2020
Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer
Andrew J Armstrong, Jun Luo, David M Nanus, et al.
Nature Communications
|
May 24, 2024
Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer
Wolfgang Beckabir, Mi Zhou, Jin Seok Lee, et al.
The Lancet. Oncology
|
May 15, 2021
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
Evan Y Yu, Daniel P Petrylak, Peter H O'Donnell, et al.
Cancer
|
August 7, 2020
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer
Tian Zhang, Michael R Harrison, Peter H O'Donnell, et al.
Page
of 19